We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Travoprost on Neovascular Glaucoma

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00441181
First Posted: February 28, 2007
Last Update Posted: June 22, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Federal University of São Paulo
  Purpose
Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma.

Condition Intervention
Neovascular Glaucoma Drug: Travoprost

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of Travoprost on Neovascular Glaucoma

Resource links provided by NLM:


Further study details as provided by Federal University of São Paulo:

Primary Outcome Measures:
  • Intraocular pressure

Secondary Outcome Measures:
  • Inflammation

Estimated Enrollment: 40
Study Start Date: January 2008
Estimated Study Completion Date: December 2008
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Neovascular glaucoma of known cause
  • Older than 18 years
  • Previously submitted to retinal photocoagulation
  • Under medical treatment to glaucoma

Exclusion Criteria:

  • Need of antiglaucomatous surgery
  • Previous ocular surgery in the last 6 months
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00441181


Locations
Brazil
Federal University of São Paulo
São Paulo, Brazil, 04023-900
Sponsors and Collaborators
Federal University of São Paulo
Investigators
Principal Investigator: Luiz A Melo Jr, MD Federal University of São Paulo
  More Information

ClinicalTrials.gov Identifier: NCT00441181     History of Changes
Other Study ID Numbers: UNIFESP 2007-02
First Submitted: February 27, 2007
First Posted: February 28, 2007
Last Update Posted: June 22, 2011
Last Verified: February 2007

Keywords provided by Federal University of São Paulo:
Neovascular glaucoma
Travoprost

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Neovascular
Ocular Hypertension
Eye Diseases
Travoprost
Antihypertensive Agents